Explore
Validate
Learn
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-91996 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-91996, RRID:AB_11034292
- Product name
- Rabbit Polyclonal HMG-CoA Reductase/HMGCR Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Specificity of human HMG-CoA Reductase/HMGCR antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Fluvastatin is effective against thymic carcinoma.
Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE-/- mice.
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Hayashi K, Nakazato Y, Morito N, Sagi M, Fujita T, Anzai N, Chida M
Life sciences 2020 Jan 1;240:117110
Life sciences 2020 Jan 1;240:117110
Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE-/- mice.
Scharinger B, Messner B, Türkcan A, Schuster D, Vuorinen A, Pitterl F, Heinz K, Arnhard K, Laufer G, Grimm M, Stuppner H, Oberacher H, Eller P, Ritsch A, Bernhard D
Journal of molecular and cellular cardiology 2016 Oct;99:35-46
Journal of molecular and cellular cardiology 2016 Oct;99:35-46
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H
BMC clinical pathology 2015;15:8
BMC clinical pathology 2015;15:8
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Bengtsson E, Nerjovaj P, Wangefjord S, Nodin B, Eberhard J, Uhlén M, Borgquist S, Jirström K
Diagnostic pathology 2014 Apr 7;9:78
Diagnostic pathology 2014 Apr 7;9:78
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O, Romero Q, Bendahl PO, Jirström K, Rydén L, Loman N, Uhlén M, Johannesson H, Rose C, Grabau D, Borgquist S
Breast cancer research and treatment 2013 Apr;138(2):499-508
Breast cancer research and treatment 2013 Apr;138(2):499-508
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: HMG-CoA Reductase/HMGCR Antibody [NBP1-91996] - Staining of human cerebral cortex shows moderate granular cytoplasmic positivity in neurons.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: HMG-CoA Reductase/HMGCR Antibody [NBP1-91996] - Staining of human kidney shows moderate granular cytoplasmic positivity in cells in tubules.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: HMG-CoA Reductase/HMGCR Antibody [NBP1-91996] - Staining of human placenta shows moderate granular cytoplasmic positivity in trophoblastic cells.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: HMG-CoA Reductase/HMGCR Antibody [NBP1-91996] - Staining of human gastrointestinal shows moderate granular cytoplasmic positivity in glandular cells.
